TUSTIN, Calif., Feb. 7 PeregrinePharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceuticalcompany developing monoclonal antibodies for the treatment of cancer andhepatitis C virus infection, today announced that senior management willpresent at the 10th Annual BIO CEO & Investor Conference on Tuesday, February12, 2008 at 9:30 am EST. The conference will be held at the Waldorf-AstoriaHotel in New York City.
Paul J. Lytle, Peregrine's chief financial officer, will provide a reviewof recent corporate developments.
A live webcast and archived replay of the company's presentation will beavailable at the Investor Relations section of Peregrine's website athttp://www.peregrineinc.com.
For more information about this conference, please visit:http://ceo.bio.org/opencms/ceo/2008/index.jsp
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with aportfolio of innovative product candidates in clinical trials for thetreatment of cancer and hepatitis C virus (HCV) infection. The company ispursuing three separate clinical programs in cancer and HCV infection with itslead product candidates bavituximab and Cotara(R). Peregrine also has in-housemanufacturing capabilities through its wholly owned subsidiary AvidBioservices, Inc. (http://www.avidbio.com), which provides development andbio-manufacturing services for both Peregrine and outside customers.Additional information about Peregrine can be found athttp://www.peregrineinc.com.Contacts: GendeLLindheim BioCom Partners Investors Media [email protected]
Barbara Lindheim (800) 987-8256 (212) 918-4650
SOURCE Peregrine Pharmaceuticals, Inc.